Galena Biopharma SLS 深 沪
已收盘 08-15 16:00:00 美东时间
1.63
+0.080
+5.16%
华盛通- 最 高1.64
- 今 开1.55
- 成交量 130.46万股
- 最 低 1.53
- 昨 收 1.55
- 总市值 1.63亿
- 52周最高 2.2691
- 市盈率 静 --
- 换手率 1.31%
- 52周最低 0.772
- 委 比 -21.43%
- 总股本 9977.75万
- 历史最高 554.50
- 量 比 0.77
- 振 幅 7.10%
- 历史最低 0.4986
- 每 手 1
- 风险率 0.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SELLAS Life Sciences Gr Q2 EPS $(0.07) Beats $(0.08) Estimate
SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 15.66 percent. This is a 46.15 percent increase over losses of $(0.13) per share
08-13 04:28
SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
SELLAS Life Sciences Group reported positive phase 2 results for SLS009 in relapsed/refractory AML, achieving a 44% response rate and 8.9-month median overall survival, well above historical benchmarks. The FDA recommends advancing SLS009 into a frontline AML trial, expected to begin enrollment in Q1 2026. Additionally, the IDMC recommended continuing the pivotal phase 3 REGAL trial of GPS in AML without modification. The company ended Q2 2025 wi...
08-12 20:05
电商资讯：TikTok联手Booking发力美国本地生活...
国内资讯 【国内电商】京东PLUS企业会员正式上线 8月9日消息，京东近日推出企业采购行业首个专属付费会员体系——京东PLUS企业会员，依托京东数智供应链能...
08-12 17:02
SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification
SELLAS Life Sciences Group announced that the Independent Data Monitoring Committee (IDMC) has positively recommended continuing its Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) without modification. The IDMC concluded that GPS's risk-benefit profile supports continued evaluation, with no safety concerns identified. Enrollment for the trial, which included 126 patients across U.S. and European sites, was completed i...
08-07 12:30
全球3D打印企业TOP15出炉，铂力特、华曙高科等企业将亮相TCT3D打印展
2025年7月31日，市场研究机构VoxelMatters发布的《2025年增材制造市场报告》显示：全球增材制造市场2024年规模达123亿美元，核心涵盖硬件...
08-04 11:08
Solaris Resources Announces Auditor Change
Solaris Resources ( ($TSE:SLS) ) has provided an update. Solaris Resources Inc....
07-30 04:48
Northrop Grumman's Sentinel Surprise Propels Analyst Confidence, Stock Forecast
Bank of America analyst maintains Buy rating for Northrop Grumman with a raised price target after Q2 revenue beat estimates and positive program progress.
07-24 03:02
美股大行评级 | 潜在涨幅264.58%！Maxim Group上调SELLAS Life Sciences目标价至7美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持SELLAS Life Sciences Gr"买入"评级，目标价从4美元升至7美元；摩根大通：维持PagSeguro Digital"中性"评级，目标价从12美元升至13美元
07-17 09:07
